A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)

PHASE3RecruitingINTERVENTIONAL

Enrollment

312

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

December 10, 2025

Study Completion Date

December 10, 2025

Conditions

Meningitis

Interventions

BIOLOGICAL

rMenB+OMV NZ vaccine

1 dose in the Primed group or 2 doses in the Naive group.

Trial Locations (3)

RECRUITING

GSK Investigational Site, Bristol

RECRUITING

GSK Investigational Site, London

RECRUITING

GSK Investigational Site, Oxford